384 related articles for article (PubMed ID: 15995290)
1. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
Yamamoto Y; Noguchi T; Udagawa N
Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
3. [Molecules which are involved in osteoclastic bone resorption: from the aspect of targets of treatment for osteoporosis].
Take I; Takahash N; Kurihara S
Clin Calcium; 2005 May; 15(5):741-6. PubMed ID: 15876734
[TBL] [Abstract][Full Text] [Related]
4. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory mechanism of bone resorption: roles of bone remodeling-regulatory cytokines 'osteokines' in osteoclast differentiation and function].
Kobayashi Y; Takahashi N
Nihon Rinsho; 2003 Feb; 61(2):200-6. PubMed ID: 12638208
[TBL] [Abstract][Full Text] [Related]
7. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
8. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Regulatory mechanisms of osteoclast differentiation and function].
Takahashi N
Clin Calcium; 2006 Jun; 16(6):940-47. PubMed ID: 16751689
[TBL] [Abstract][Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
Ueland T; Bollerslev J; Mosekilde L
Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and bone.
Suda T; Ueno Y; Fujii K; Shinki T
J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
[TBL] [Abstract][Full Text] [Related]
12. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
14. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
Sabokbar A; Itonaga I; Sun SG; Kudo O; Athanasou NA
J Orthop Res; 2005 May; 23(3):511-9. PubMed ID: 15885469
[TBL] [Abstract][Full Text] [Related]
15. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the differentiation and function of osteoclasts.
Chambers TJ
J Pathol; 2000 Sep; 192(1):4-13. PubMed ID: 10951393
[TBL] [Abstract][Full Text] [Related]
17. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
18. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
19. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics.
Zaidi M; Blair HC; Moonga BS; Abe E; Huang CL
J Bone Miner Res; 2003 Apr; 18(4):599-609. PubMed ID: 12674320
[TBL] [Abstract][Full Text] [Related]
20. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]